Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | APAF1 | O14727 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | RYR2 | Q92736 | 3/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22232989 | 0.86 | MEN1 (0.55) | MEN1GAAKMT2AALDH1A1KDM4E | |
| SCHEMBL8038619 | 0.77 | MEN1 (0.53) | MEN1GAAKMT2AALDH1A1RYR2 | |
| SCHEMBL1816443 | 0.77 | MEN1 (0.53) | MEN1GAAKMT2AALDH1A1MAPT | |
| SCHEMBL616341 | 0.77 | MEN1 (0.53) | MEN1GAAKMT2AALDH1A1MAPT | |
| SCHEMBL10226479 | 0.77 | GAA (0.53) | MEN1GAAKMT2AALDH1A1KDM4E | |
| SCHEMBL22258218 | 0.76 | MEN1 (0.43) | MEN1GAAKMT2AALDH1A1KDM4E | |
| SCHEMBL2363066 | 0.75 | ALDH1A1 (0.47) | MEN1GAAKMT2AALDH1A1MAPT | |
| SCHEMBL4758944 | 0.74 | CA1 (0.49) | MEN1GAAKMT2AALDH1A1KDM4E | |
| SCHEMBL12692912 | 0.73 | ALDH1A1 (0.49) | MEN1GAAKMT2AALDH1A1MAPT | |
| SCHEMBL3070838 | 0.73 | MEN1 (0.49) | MEN1GAAKMT2AALDH1A1RYR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107372-A1 | 2-(Quinolonyl)-fused heterocycles as androgen receptor modulators | LANTER JAMES C (US) | 2005-05-19 | — | — | US | disclosed |
| US-6858621-B2 | 2-(quinolonyl)-fused heterocycles as androgen receptor modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1501835-A2 | 2-(QUINOLONYL)-FUSED HETEROCYCLES AS ANDROGEN RECEPTOR MODULATORS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040014743-A1 | 2-(Quinolonyl)-fused heterocycles as androgen receptor modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-01-22 | — | — | US | disclosed |
| WO-2003090672-A2 | 2-(QUINOLONYL)-FUSED HETEROCYCLES AS ANDROGEN RECEPTOR MODULATORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014743-A1 | 2-(Quinolonyl)-fused heterocycles as androgen receptor modulators | AR, NR5A1, ESRRA | MEN1 2365/4885GAA 3667/4885KMT2A 2048/4885 |
| US-20050107372-A1 | 2-(Quinolonyl)-fused heterocycles as androgen receptor modulators | AR, NR5A1, CYP19A1 | MEN1 2058/4885GAA 4041/4885KMT2A 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.